Advertisement

Correction to: Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands

Correction to: Applied Health Economics and Health Policy (2019) 17:857–873 https://doi.org/10.1007/s40258-019-00500-8

The second author’s name should be “Maria De Francesco” rather than “Maria de Fransesco”.

The corresponding author’s email address should be “Marieke.Krol@iqvia.com” rather than “mkrol@iqvia.com”.

Author information

Correspondence to Marieke Krol.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Michels, R.E., De Francesco, M., Mahajan, K. et al. Correction to: Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands. Appl Health Econ Health Policy (2020) doi:10.1007/s40258-019-00548-6

Download citation